Combo bests standard care in younger CLL patients

Print Friendly, PDF & Email


2018 ASH Annual Meeting
©ASH/Scott Morgan 2018
In a phase 3 trial, ibrutinib plus rituximab (IR) improved survival when compared with standard chemoimmunotherapy in patients younger than 70 with untreated chronic lymphocytic leukemia (CLL). Patients who received IR had superior progression-free survival (PFS) and overall survival compared to patients who received fludarabine, cyclophosphamide, and rituximab... [Read Article]
Print Friendly, PDF & Email

Preliminary data suggest UCART19 is safe, effective

Print Friendly, PDF & Email


Reuben Benjamin, MD, PhD
Photo by Jen Smith
Preliminary data on UCART19—the first off-the-shelf, anti-CD19, allogeneic chimeric antigen receptor (CAR) T-cell therapy—suggest it can produce complete responses (CRs) and minimal residual disease (MRD) negativity, and side effects are manageable. Investigators pooled data from the phase 1 pediatric (PALL) and adult (CALM) trials of UCART19... [Read Article]
Print Friendly, PDF & Email

Dasatinib re-challenge feasible as 2nd attempt at TKI discontinuation

Print Friendly, PDF & Email


Dennis Kim, MD
Photo by Jen Smith
Preliminary trial results suggest re-treatment with dasatinib is feasible and safe for a second attempt at tyrosine kinase inhibitor (TKI) discontinuation in chronic myeloid leukemia (CML) patients who fail to achieve treatment-free remission (TFR) after discontinuing imatinib. However, investigators reported the rate of second TFR (TFR2) was 21%... [Read Article]
Print Friendly, PDF & Email

ALL regimens clear disease in kids with MPAL

Print Friendly, PDF & Email


2018 ASH Annual Meeting
Photo by Jen Smith
Pediatric patients with mixed phenotype acute leukemia (MPAL) can achieve minimal residual disease (MRD) negativity with acute lymphoblastic leukemia (ALL)-directed chemotherapy, according to new research. In a retrospective study, most pediatric MPAL patients who received ALL-directed chemotherapy achieved an MRD-negative complete response (CR). Ninety-three percent of patients... [Read Article]
Print Friendly, PDF & Email

Serious side effect of AML treatment going unnoticed, FDA warns

Print Friendly, PDF & Email


Enasidenib (Idhifa®)
Photo from Business Wire
The U.S. Food and Drug Administration (FDA) has released a safety communication warning that cases of differentiation syndrome are going unnoticed in patients treated with the IDH2 inhibitor enasidenib (Idhifa). Enasidenib is FDA-approved to treat adults with relapsed or refractory acute myeloid leukemia (AML) and an IDH2... [Read Article]
Print Friendly, PDF & Email

Pegfilgrastim biosimilar approved by EC

Print Friendly, PDF & Email


Nurse bandaging
chemotherapy patient
Photo by Rhoda Baer
The European Commission (EC) has granted marketing authorization for Sandoz’s pegfilgrastim product Ziextenzo®, a biosimilar of Amgen’s Neulasta. Ziextenzo is approved for the same use as the reference medicine—to reduce the duration of neutropenia and the incidence of febrile neutropenia in adults receiving cytotoxic chemotherapy for... [Read Article]
Print Friendly, PDF & Email

EC approves pegfilgrastim biosimilar

Print Friendly, PDF & Email


Cancer patient receiving chemotherapy
Photo by Rhoda Baer
The European Commission (EC) has approved Mundipharma’s pegfilgrastim product Pelmeg, a biosimilar of Amgen’s Neulasta. Pelmeg is approved for use in reducing the duration of neutropenia and the incidence of febrile neutropenia in adults who receive cytotoxic chemotherapy for malignancies, with the exceptions of chronic... [Read Article]
Print Friendly, PDF & Email

FDA approves venetoclax for AML

Print Friendly, PDF & Email


Venetoclax
Photo courtesy of Abbvie
The U.S. Food and Drug Administration (FDA) has granted accelerated approval to venetoclax (Venclexta®) for use in acute myeloid leukemia (AML). The BCL-2 inhibitor is now approved for use in combination with azacitidine, decitabine, or low-dose cytarabine to treat adults with newly diagnosed AML who are age 75 and... [Read Article]
Print Friendly, PDF & Email

FDA approves glasdegib for AML

Print Friendly, PDF & Email


AML cells
Image by Lance Liotta
The U.S. Food and Drug Administration (FDA) has approved the hedgehog pathway inhibitor glasdegib (Daurismo™) to treat certain patients with acute myeloid leukemia (AML). Glasdegib is approved for use in combination with low-dose cytarabine (LDAC) to treat adults with newly diagnosed AML who are age 75 and older... [Read Article]
Print Friendly, PDF & Email